Simon Quick Advisors LLC Acquires 444 Shares of Natera, Inc. $NTRA

Simon Quick Advisors LLC boosted its holdings in Natera, Inc. (NASDAQ:NTRA) by 27.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,045 shares of the medical research company’s stock after acquiring an additional 444 shares during the period. Simon Quick Advisors LLC’s holdings in Natera were worth $345,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in NTRA. GAMMA Investing LLC increased its position in Natera by 32.3% during the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company’s stock worth $120,000 after buying an additional 207 shares during the period. Amalgamated Bank increased its position in Natera by 9.8% during the 1st quarter. Amalgamated Bank now owns 8,293 shares of the medical research company’s stock worth $1,173,000 after buying an additional 740 shares during the period. Private Trust Co. NA increased its position in Natera by 780.1% during the 1st quarter. Private Trust Co. NA now owns 1,461 shares of the medical research company’s stock worth $207,000 after buying an additional 1,295 shares during the period. Calamos Advisors LLC increased its position in Natera by 29.0% during the 1st quarter. Calamos Advisors LLC now owns 29,637 shares of the medical research company’s stock worth $4,191,000 after buying an additional 6,667 shares during the period. Finally, Ninety One UK Ltd bought a new position in Natera during the 1st quarter worth $31,959,000. Institutional investors own 99.90% of the company’s stock.

Insiders Place Their Bets

In related news, insider Solomon Moshkevich sold 1,198 shares of the firm’s stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $191.46, for a total value of $229,369.08. Following the sale, the insider directly owned 115,061 shares of the company’s stock, valued at $22,029,579.06. This trade represents a 1.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Steven Leonard Chapman sold 3,680 shares of the firm’s stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $191.46, for a total value of $704,572.80. Following the completion of the sale, the chief executive officer directly owned 149,840 shares in the company, valued at $28,688,366.40. This trade represents a 2.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 61,064 shares of company stock valued at $10,477,848. 5.63% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Stephens reiterated an “overweight” rating and set a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. BNP Paribas Exane upgraded Natera from an “underperform” rating to a “neutral” rating and set a $172.00 price objective on the stock in a research report on Monday, October 27th. Morgan Stanley reiterated an “overweight” rating and set a $195.00 price objective on shares of Natera in a research report on Sunday, August 10th. Finally, Barclays reiterated an “overweight” rating and set a $210.00 price objective (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $194.89.

Natera Stock Performance

NTRA opened at $198.93 on Monday. The firm has a market cap of $27.30 billion, a P/E ratio of -104.15 and a beta of 1.74. Natera, Inc. has a 52-week low of $120.67 and a 52-week high of $199.21. The business’s fifty day moving average is $174.44 and its 200-day moving average is $162.08.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period last year, the company posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. On average, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.